• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

单克隆抗体RS7-3G11的特异性和特性以及由这种泛癌单克隆抗体所定义的抗原

Specificity and properties of MAb RS7-3G11 and the antigen defined by this pancarcinoma monoclonal antibody.

作者信息

Stein R, Basu A, Chen S, Shih L B, Goldenberg D M

机构信息

Garden State Cancer Center, Center for Molecular Medicine and Immunology, Newark, NJ 07103.

出版信息

Int J Cancer. 1993 Dec 2;55(6):938-46. doi: 10.1002/ijc.2910550611.

DOI:10.1002/ijc.2910550611
PMID:8253531
Abstract

The murine monoclonal antibody (MAb) RS7-3G11 is an IgG1 with pancarcinoma reactivity, which has been raised against human squamous-cell carcinoma of the lung. Immunoperoxidase staining of frozen tissue sections demonstrated that the antigen defined by RS7-3G11 is present in tumors of the lung, stomach, bladder, breast, ovary, uterus and prostate. The rate and extent of internalization of RS7-3G11 into Calu-3, an adenocarcinoma of the lung cell line, was investigated using unconjugated MAb, followed by fluorescence labelling, and by binding 125I-RS7-3G11 followed by acid removal of surface-bound antibody. Rapid internalization of MAb RS7-3G11 into target cells was observed. Antibody internalization was noted at 30 min, and by 2 hr virtually all MAb RS7-3G11 was internal. Although MAb RS7-3G11 was raised against non-small-cell carcinoma of the lung, ME-180, a cervical-carcinoma cell line, expresses higher quantities of the antigen than the lung-carcinoma cell lines. Due to the higher antigen density in ME-180 cells, this line was used for immunoprecipitation studies and antigen purification. Immunoprecipitation studies using the ME-180 cervical-carcinoma cell line metabolically labeled with [3H]leucine or [3H]glucosamine demonstrated that the antigen defined by RS7-3G11 is a glycoprotein of M(r) 46 kDa. Deglycosylation by treatment with endoglycosidase-F resulted in a protein with a M(r) of 35 kDa. RS7-3G11-antigen was purified from ME-180 tissue-culture cells using affinity-column chromatography. By SDS-PAGE it was seen that the antigen was highly purified. The major band appeared at M(r) of 45 to 48 kDa. This result is in agreement with the immunoprecipitation studies. The broad band observed in the SDS-PAGE is typical of many glycoproteins, and suggests heterogeneity of glycosylation. Chemical and enzymatic treatments of the antigen, followed by Western blot analyses, suggest that the RS7-3G11 antigenic determinant is composed of a conformation-dependent peptide.

摘要

鼠单克隆抗体(MAb)RS7-3G11是一种具有泛癌反应性的IgG1,它是针对人肺鳞状细胞癌产生的。对冷冻组织切片进行免疫过氧化物酶染色显示,RS7-3G11所定义的抗原存在于肺、胃、膀胱、乳腺、卵巢、子宫和前列腺的肿瘤中。使用未偶联的单克隆抗体,随后进行荧光标记,并通过结合125I-RS7-3G11,然后用酸去除表面结合的抗体,研究了RS7-3G11内化到肺腺癌细胞系Calu-3中的速率和程度。观察到单克隆抗体RS7-3G11迅速内化到靶细胞中。在30分钟时注意到抗体内化,到2小时时,几乎所有的单克隆抗体RS7-3G11都已内化。尽管单克隆抗体RS7-3G11是针对肺非小细胞癌产生的,但宫颈癌细胞系ME-180表达的该抗原量比肺癌细胞系更高。由于ME-180细胞中抗原密度更高,该细胞系被用于免疫沉淀研究和抗原纯化。使用用[3H]亮氨酸或[3H]葡糖胺代谢标记的ME-180宫颈癌细胞系进行免疫沉淀研究表明,RS7-3G11所定义的抗原是一种分子量为46 kDa的糖蛋白。用内切糖苷酶-F处理进行去糖基化后,得到一种分子量为35 kDa的蛋白质。使用亲和柱色谱从ME-180组织培养细胞中纯化RS7-3G11抗原。通过SDS-PAGE可以看出抗原得到了高度纯化。主要条带出现在分子量为45至48 kDa处。这一结果与免疫沉淀研究一致。在SDS-PAGE中观察到的宽带是许多糖蛋白的典型特征,表明糖基化存在异质性。对抗原进行化学和酶处理,随后进行蛋白质印迹分析,表明RS7-3G11抗原决定簇由一个构象依赖性肽组成。

相似文献

1
Specificity and properties of MAb RS7-3G11 and the antigen defined by this pancarcinoma monoclonal antibody.单克隆抗体RS7-3G11的特异性和特性以及由这种泛癌单克隆抗体所定义的抗原
Int J Cancer. 1993 Dec 2;55(6):938-46. doi: 10.1002/ijc.2910550611.
2
Murine monoclonal antibodies raised against human non-small cell carcinoma of the lung: specificity and tumor targeting.针对人非小细胞肺癌产生的鼠单克隆抗体:特异性与肿瘤靶向性。
Cancer Res. 1990 Feb 15;50(4):1330-6.
3
The epithelial/carcinoma antigen EGP-1, recognized by monoclonal antibody RS7-3G11, is phosphorylated on serine 303.上皮/癌抗原EGP-1,可被单克隆抗体RS7-3G11识别,其丝氨酸303位点发生磷酸化。
Int J Cancer. 1995 Aug 9;62(4):472-9. doi: 10.1002/ijc.2910620419.
4
Characterization of cluster 13: the epithelial/carcinoma antigen recognized by MAb RS7.13号簇的特征:单克隆抗体RS7识别的上皮/癌抗原
Int J Cancer Suppl. 1994;8:98-102. doi: 10.1002/ijc.2910570721.
5
In vitro and in vivo reactivity of an internalizing antibody, RS7, with human breast cancer.内化抗体RS7与人乳腺癌的体外和体内反应性
Cancer Res. 1995 Dec 1;55(23 Suppl):5857s-5863s.
6
Comparative biodistribution and radioimmunotherapy of monoclonal antibody RS7 and its F(ab')2 in nude mice bearing human tumor xenografts.单克隆抗体RS7及其F(ab')2在荷人肿瘤异种移植裸鼠中的比较生物分布和放射免疫治疗
Cancer. 1994 Feb 1;73(3 Suppl):816-23. doi: 10.1002/1097-0142(19940201)73:3+<816::aid-cncr2820731311>3.0.co;2-t.
7
[Immunoscintigraphy of anti-type IV collagenase monoclonal antibody in nude mice bearing human lung cancer xenograft].抗IV型胶原酶单克隆抗体在荷人肺癌裸鼠中的免疫闪烁显像
Ai Zheng. 2003 Dec;22(12):1243-8.
8
Characterization of the colorectal carcinoma-associated antigen defined by monoclonal antibody D612.由单克隆抗体D612所定义的结肠直肠癌相关抗原的特性分析
Cancer Res. 1991 Feb 1;51(3):926-34.
9
Tissue distribution, immunochemical characterization, and biosynthesis of 47D10, a tumor-associated surface glycoprotein.肿瘤相关表面糖蛋白47D10的组织分布、免疫化学特性及生物合成
Cancer Res. 1987 Jan 1;47(1):241-50.
10
Monoclonal antibody targeting of human non-small cell carcinoma of the lung.
Cancer Res. 1990 Feb 1;50(3 Suppl):866s-868s.

引用本文的文献

1
Advances in antibody-drug conjugates in the treatment of advanced triple-negative breast cancer: a narrative review.抗体药物偶联物在晚期三阴性乳腺癌治疗中的进展:一项叙述性综述。
Transl Breast Cancer Res. 2025 Jan 21;6:9. doi: 10.21037/tbcr-24-38. eCollection 2025.
2
Targeting Refractory Triple-Negative Breast Cancer with Sacituzumab Govitecan: A New Era in Precision Medicine.用戈沙妥珠单抗靶向难治性三阴性乳腺癌:精准医学的新时代。
Cells. 2024 Dec 22;13(24):2126. doi: 10.3390/cells13242126.
3
Novel Anti-Trop2 Nanobodies Disrupt Receptor Dimerization and Inhibit Tumor Cell Growth.
新型抗Trop2纳米抗体破坏受体二聚化并抑制肿瘤细胞生长。
Pharmaceutics. 2024 Sep 27;16(10):1255. doi: 10.3390/pharmaceutics16101255.
4
The Relationship between Trop-2, Chemotherapeutic Drugs, and Chemoresistance.Trop-2 与化疗药物及化疗耐药性的关系。
Int J Mol Sci. 2023 Dec 20;25(1):87. doi: 10.3390/ijms25010087.
5
Unlocking New Horizons in Small-Cell Lung Cancer Treatment: The Onset of Antibody-Drug Conjugates.开启小细胞肺癌治疗的新视野:抗体药物偶联物的出现
Cancers (Basel). 2023 Nov 10;15(22):5368. doi: 10.3390/cancers15225368.
6
A literature review of the promising future of : a potential drug therapy target.关于:一个潜在药物治疗靶点的光明未来的文献综述。
Ann Transl Med. 2022 Dec;10(24):1403. doi: 10.21037/atm-22-5976.
7
Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021.小分子抑制剂、免疫检查点抑制剂等:1991 年至 2021 年美国食品和药物管理局批准用于实体瘤的新型治疗药物。
J Hematol Oncol. 2022 Oct 8;15(1):143. doi: 10.1186/s13045-022-01362-9.
8
Impact of Endocytosis Mechanisms for the Receptors Targeted by the Currently Approved Antibody-Drug Conjugates (ADCs)-A Necessity for Future ADC Research and Development.内吞作用机制对目前已获批抗体药物偶联物(ADC)所靶向受体的影响——未来ADC研发的必要性
Pharmaceuticals (Basel). 2021 Jul 15;14(7):674. doi: 10.3390/ph14070674.
9
Treating Bladder Cancer: Engineering of Current and Next Generation Antibody-, Fusion Protein-, mRNA-, Cell- and Viral-Based Therapeutics.治疗膀胱癌:当前及下一代基于抗体、融合蛋白、信使核糖核酸、细胞和病毒的治疗方法的工程学
Front Oncol. 2021 May 27;11:672262. doi: 10.3389/fonc.2021.672262. eCollection 2021.
10
Trop2: Jack of All Trades, Master of None.滋养层细胞2:样样皆通,样样稀松。
Cancers (Basel). 2020 Nov 11;12(11):3328. doi: 10.3390/cancers12113328.